BioCardia’s (BCDA) Buy Rating Reaffirmed at HC Wainwright

BioCardia (NASDAQ:BCDA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $25.00.

BioCardia Trading Down 10.7%

BCDA stock opened at $0.92 on Tuesday. The firm has a market cap of $10.47 million, a PE ratio of -1.01 and a beta of 0.51. The stock has a 50-day moving average price of $1.08 and a 200-day moving average price of $1.21. BioCardia has a 1-year low of $0.84 and a 1-year high of $2.45.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). On average, analysts forecast that BioCardia will post -0.71 earnings per share for the current year.

Institutional Trading of BioCardia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DRW Securities LLC bought a new stake in BioCardia in the 4th quarter valued at about $72,000. Geode Capital Management LLC lifted its stake in BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares during the last quarter. Finally, Cetera Investment Advisers purchased a new position in BioCardia in the second quarter valued at approximately $40,000. 20.57% of the stock is owned by institutional investors.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.